New combo therapy aims to starve and poison liver tumors
NCT ID NCT02174549
First seen Apr 24, 2026 · Last updated Apr 28, 2026 · Updated 1 time
Summary
This early-phase trial tests a drug called tirapazamine, which becomes active in low-oxygen areas, combined with a procedure that blocks blood flow to liver tumors (embolization). The goal is to find the best dose and see how well the treatment shrinks tumors. The study includes up to 25 adults with liver cancer or liver-dominant neuroendocrine tumors that are not suitable for surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94305, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.